SEARCH

SEARCH BY CITATION

References

  • Bauermeister, D.E. (1971) Quantitation of bone marrow reticulin – a normal range. American Journal of Clinical Pathology, 56, 2431.
  • Van Besien, K. & Deeg, H.J. (2005) Hematopoietic stem cell transplantation for myelofibrosis. Seminars in Oncology, 32, 414421.
  • Campbell, P.J., Griesshammer, M., Dohner, K., Dohner, H., Kusec, R., Hasselbalch, H.C., Larsen, T.S., Pallisgaard, N., Giraudier, S., Le Bousse-Kerdiles, M.C., Desterke, C., Guerton, B., Dupriez, B., Bordessoule, D., Fenaux, P., Kiladjian, J.J., Viallard, J.F., Briere, J., Harrison, C.N., Green, A.R. & Reilly, J.T. (2006). The V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood, 107, 20982100.
  • Cervantes, F., Pereira, A., Esteve, J., Rafel, M., Cobo, F., Rozman, C. & Montserrat, E. (1997) Identification of ‘‘long-lived’’ and ‘‘ short-lived’’ patients at presentation of primary myelofibrosis. British Journal of Haematology, 97, 635640.
  • Cervantes, F., Rovira, M. & Urbano-Ispizua, A. (2000) Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplantation, 26, 697699.
  • Daly, A., Song, K. & Nevill, T. (2003) Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplantation, 32, 32353240.
  • Deeg, H.J., Gooley, T.A. & Flowers, M.E. (2003) Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood, 102, 39123918.
  • Devine, S.M., Hoffman, R. & Verma, A. (2002) Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood, 99, 22552258.
  • Ditschkowski, M., Beelen, D.W. & Trenschel, R. (2004) Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplantation, 34, 807813.
  • Dupriez, B., Morel, P. & Demory, J.L. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 10131018.
  • Greyz, N., Miller, W.E., Andrey, J. & Mason, J. (2004) Long-term remission of myelofibrosis following nonmyeloablative allogeneic peripheral blood progenitor cell transplantation in older age: the Scripps Clinic experience. Bone Marrow Transplantation, 34, 273274.
  • Guardiola, P., Anderson, J.E. & Bandini, G. (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood, 93, 28312838.
  • Guardiola, P., Deeg, H.J., Anderson, J.E., De Witte, T. & Gluckman, E. (2002) Transplantation for myelofibrosis with myeloid metaplasia. Haematologica, 87(Suppl.), 5358.
  • Hessling, J., Kroger, N., Werner, M., Zabelina, T., Hansen, A., Kordes, U., Ayuk, F.A., Renes, H., Panse, J., Erttmann, R. & Zander, A.R. (2002) Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 119, 769772.
  • Johansson, P., Kutti, J., Andreasson, B., Safai-Kutti, S., Vilén, L., Wedel, H. & Ridell, B. (2004) Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Góteborg, Sweden, during 1983–99. Journal of Internal Medicine, 256, 161165.
  • Kröger, N., Zabelina, T., Schieder, H., Panse, J., Ayuk, F., Stute, N., Fehse, N., Waschke, O., Fehse, B., Kvasnicka, H.M., Thiele, J. & Zander, A. (2005). Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. British Journal of Haematology, 128, 690697.
  • Mesa, R.A., Powell, H., Lasho, T., Dewald, G., McClure, R. & Tefferi, A. (2006a) A longitudinal study of the JAK2V617F mutation in myelofibrosis with myeloid metaplasia: analysis at two time points. Haematologica, 91, 415416.
  • Mesa, R.A., Powell, H., Lasho, T., Dewald, G., McClure, R. & Tefferi, A. (2006b) JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia Leukemia Research 30, 14571460.
  • Rondelli, D., Barosi, G. & Bacigalupo, A. (2005) Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood, 105, 41154119.
  • Tanner, M.L., Hoh, C.K., Bashey, A., Holman, P., Sun, C., Broome, H.E., Lane, T., Ball, E.D. & Carrier, E. (2003) FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia. Bone Marrow Transplantation, 32, 581585.
  • Thiele, J., Kvasnicka, H.M., Dietrich, H., Stein, G., Hann, M., Kaminski, A., Rathjen, N., Metz, K.A., Beelen, D.W., Ditschkowski, M., Zander, A. & Kroeger, N. (2005) Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histology and Histopathology, 20, 879889.